Health Trials

HR+, HER2-, Advanced Breast Cancer

3

Review clinical trials related to HR+, HER2-, Advanced Breast Cancer. Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Recruiting

ORION-1: Study of AVZO-023 as a Single Agent and in Combination With AVZO-021, and/or Endocrine Therapy in Advanced Solid Tumors

This study, the first clinical trial of AVZO-023, aims to determine the safety, tolerability, pharmacokinetics (PK), pharmacodynamics, maximum tolerated dose, and anti-tumor effects of AVZO-023 in patients with advanced solid tumors. AVZO-023 is an oral medication that inhibits cyclin-dependent kinase 4 (CDK4).

Participants needed: 380
Trial details
Phase: Phase 1, Phase 2Age: 18+Biological sex: AllType: InterventionalSponsor: Avenzo Therapeutics, Inc.Updated: May 4, 2026Locations: 14
Eligibility criteria

Male or female aged ≥ 18 years old at screening with Eastern Cooperative Oncolog... [+4]

Patients should not have received any prior selective investigational CDK (CDK2,... [+10]

Read more
Status: Recruiting

Study of AVZO-021 in Patients With Advanced Solid Tumors

This study, the first clinical trial of AVZO-021, aims to determine the safety, tolerability, pharmacokinetics, pharmacodynamics, maximum tolerated dose, and anti-tumor effects of AVZO-021 in patients with advanced solid tumors. AVZO-021 is an oral medication that inhibits cyclin-dependent kinase 2 (CDK 2).

Participants needed: 430
Trial details
Phase: Phase 1, Phase 2Age: 18+Biological sex: AllType: InterventionalSponsor: Avenzo Therapeutics, Inc.Updated: Nov 19, 2025Locations: 13
Eligibility criteria

Male or female aged ≥18 years old at screening with Eastern Cooperative Oncology... [+4]

Received an investigational agent or anticancer therapy within 2 weeks, or 5 hal... [+10]

Read more
Status: Recruiting

A Study of Invikafusp Alfa (STAR0602), a Selective T Cell Receptor (TCR)-Targeting, Bifunctional Antibody-fusion Molecule, in Combination With Sacituzumab Govitecan in Participants With Advanced Solid Tumors

This is a Phase 1b/2, Open-label Study to Investigate the Safety and Efficacy of Invikafusp alfa (STAR0602), a Selective T Cell Receptor (TCR)-targeting, Bifunctional Antibody-fusion Molecule, in Combination with Sacituzumab Govitecan in Participants with Unresectable, Locally Advanced, or Metastatic Solid Tumors.

Participants needed: 50
Trial details
Phase: Phase 1, Phase 2Age: 18+Biological sex: AllType: InterventionalSponsor: Marengo Therapeutics, Inc.Updated: Sep 24, 2025Locations: 8
Eligibility criteria

Have measurable disease as per RECIST v1.1 criteria and documented by CT and/or... [+2]

Vitiligo [+16]

Read more